Concord Biotech appoints Mr Raviraj Karia as new Chief Financial Officer

Management Changes View source PDF Explain this filing

CONCORDBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.5%Reaction day

₹1328.10

prior close

₹1331.10

announcement price

In-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-0.1%+1.6% vs market

Pharmaceuticals peers, median of 152sector-0.5%+2.0% vs sector

On the reaction day the stock moved 1.6 pts more than Nifty Smallcap 250 and 2.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.1

10m

+0.0

15m

-0.1

30m

-0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.5-0.1+1.6-0.5+2.0

Next day

+1.0+1.2-0.2+0.5+0.4

-0.1+2.2-2.3+1.0-1.1

+1.3+2.6-1.3+1.1+0.2

+1.3+2.7-1.3+0.9+0.4

+1.0+2.5-1.4+0.5+0.5

+0.9+1.7-0.8-0.3+1.2

15d

-0.8-0.0-0.8-0.3-0.5

-1.8-1.2-0.7-2.7+0.9

-13.4-0.2-13.2-2.4-11.1

-14.0-6.5-7.5-8.9-5.1

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 152Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Concord Biotech's Board has appointed Mr Raviraj Karia as the new Chief Financial Officer and Key Managerial Personnel, effective December 18, 2025. He is a Chartered Accountant with over 23 years of experience across pharmaceuticals, healthcare, clinical research, logistics, and private equity, having held senior finance roles at Intas Pharmaceuticals, Sakar Healthcare, Lambda Therapeutics, Shalby Hospitals, Gati, GVFL, and Claris Lifesciences. He holds no shares and is not related to any Director.

Likely market impact

Routine KMP change; experienced pharma finance hire supports continuity in financial governance and strategy execution.